Abstract 348P
Background
Malignant melanoma is an extremely rare malignancy in the Indian subcontinent and South east Asia. Its already known that Asian countries have different clinical presentation of melanoma. It would be interesting to know the epidemiology and outcome of advanced disease in Indian patients.
Methods
We retrospectively analysed patients with malignant melanoma who were registered in Medical Oncology clinic at AIIMS, New Delhi between January 2016 and July 2019. We used SPSS version 23 for analysis. Immunotherapy used was single agent Nivolumab as Ipilimumab is unavailable.
Results
Total of 93 patients (57 males, 36 females) were registered in the study. Median age was 53 (range, 25 to 85 years), with the commonest primary sites being anorectal (n = 23) and foot (n = 23), followed by eye (n = 15), head and neck (n = 12), thigh (n = 9), others (n = 11) respectively. The commonest sites of metastasis were lymph nodes (n = 54, 58.1%), lung (n = 45,48.4%), liver(n = 33,35.5%) and bone(n = 25,26.9%).The median sites of metastasis was two (range 1-5). Most patients had ECOG PS 1-2 (n = 77, 82.8%). Majority of the patients (n = 80,86%) had metastasis.Out of 93 patients, 39(42%) received chemotherapy in first line, 16 (17.3%) received Immunotherapy, 13 (13.9%) underwent surgery and best supportive care was offered to 25 (26.8%) patients. The chemotherapy used were dacarbazine (n = 27), nabpaclitaxel (n = 6) and others (n = 6). Among patients who received chemo, median number of cycles was 5 (range,1-15) and response assessment revealed progressive disease in 17 patients, stable disease in 4 patients, partial response in one patient, and remaining 16 patients defaulted and were not evaluable. Among patients who received Single agent Nivolumab, the median number of cycles was 5 (range,2-15) and response showed progressive disease in all patients, except one. Median follow up was 18 months and median PFS was 3 months.
Conclusions
This study shows that the site of melanoma in Indian patients is different as compared to western patients with higher number of anorectal, mucosal and acral melanoma. Immunotherapy was feasible for only a fraction of patients in view of exorbitant cost. Non availability of BRAF therapies and Ipilimumab is of great concern in view of poor outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract